Ion Beam Applications SA

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP

B5317W146
SEDOL

B28ZTN6
CIK

N/A

iba-worldwide.com
LEI: 5493002RVRZ1S3CPUI26
FIGI: BBG000BCXPJ8
IBAB

Ion Beam Applications SA
GICS: 35101010 · Sector: - · Sub-Sector: -
AI
PROFILER
NAME
Ion Beam Applications SA
ISIN
BE0003766806
TICKER
IBAB
MIC
XBRU
REUTERS
IBAB.BR
BLOOMBERG
IBAB BB
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants

GlobeNewswire is an important news source that provides investors with company-related information. In particular, it deals with events that may be relevant to the listing of companies or tradable financial instruments. You can access the complete overview of all reports via this link.

Tue, 18.02.2025

Louvain-la-Neuve, Belgium, 18 February, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, will host a Capital Markets Day (CMD) for investors and analysts on Monday 7 April 2025 at 2pm CET / 1pm GMT / 8am ET.

Tue, 11.02.2025

Tue, 11.02.2025

Fri, 07.02.2025

Louvain-La-Neuve, Belgium, and Paris, France, 7 February 2025 - Framatome, an international leader in nuclear energy committed to developing products and services for the healthcare industry, and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today announced they have signed a Memorandum Of Understanding to start a strategic partnership aimed at advancing industrial-scale production of Astatine-211 (211At), an alpha-emitting radioisotope across Europe and the United States.

Thu, 06.02.2025

Louvain-La-Neuve, Belgium, February 06, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a binding agreement with the Asian Institute of Gastroenterology (AIG) for the supply of a Proteus®ONE1 compact proton therapy system to be located at the new Oncology Centre within AIG Hospitals’ Gachibowli campus in Hyderabad, India. The first payment has been received.

Tue, 21.01.2025

Fri, 17.01.2025

 Louvain-La-Neuve, Belgium, January 17, 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that Soumya Chandramouli will be stepping down from her role as Chief Financial Officer (“CFO”), effective 31 January 2025. Henri de Romrée, Deputy CEO, will oversee the financial direction at Group level until a new CFO has been appointed. Thomas Pevenage, Finance Director, will continue to lead the Group’s Investor Relations function until further notice.

Fri, 10.01.2025

Confirmation of the sale of IBA shares to Management Anchorage

Fri, 06.12.2024

NOTICE OF A GENERAL MEETING OF IBA SA

Thu, 21.11.2024

Louvain-la-Neuve, Belgium, 21 November 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2024.

We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S